Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer

Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. EGFR TKIs induce dramatic objective responses and increase survival in patients bearing sensitizing mutations in the EGFR intr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Noto, Alessia, De Vitis, Claudia, Roscilli, Giuseppe, Fattore, Luigi, Malpicci, Debora, Marra, Emanuele, Luberto, Laura, D'Andrilli, Antonio, Coluccia, Pierpaolo, Giovagnoli, Maria Rosaria, Normanno, Nicola, Ruco, Luigi, Aurisicchio, Luigi, Mancini, Rita, Ciliberto, Gennaro
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2013
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3787155/
https://ncbi.nlm.nih.gov/pubmed/23896512
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk